Christopher Starr, Raptor Pharma's (RPTP) CEO since 2006, will be retiring at year's end. COO Julie Anne Smith will replace him.
Starr will remain on Raptor's board following his resignation as CEO, and will conitnue to "consult on Raptor development projects."
Smith has been Raptor's COO since Sep. '12. Prior to joining Raptor, she was the sales chief for Enobia Pharma.